Orchard Therapeutics PLC

Orchard Therapeutics — 2021 JP Morgan Healthcare Conference

23 slides from Orchard Therapeutics's conference presentation, Jan 11, 2021

  1. Slide 1: 2021 JP Morgan Presentation

    Slide 1: 2021 JP Morgan Presentation

    2021 JP Morgan Presentation Bobby Gaspar, M.D., Ph.D. Chief executive officer January 13, 2021 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    Certain information set forth in this presentation and in statements made orally during this presentation contains “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and may include, but is not limited to, the C

  3. Slide 3: Curing the incurable: The potential of HSC gene therapy

    Slide 3: Curing the incurable: The potential of HSC gene therapy

    Curing the incurable The potential of HSC gene therapy

  4. Slide 4: A Vision for Long-term Growth and Value Creation

    Slide 4: A Vision for Long-term Growth and Value Creation

    A Vision for Long-term Growth and Value Creation GT, gene therapy 4 TIME VALUE Execute and deliver on rare diseases Build out capabilities in HSC GT across regulatory, manufacturing, commercialization and access Partnership opportunities Focus on HSC GT for larger indications Partnership opportuniti

  5. Slide 5: We Are Delivering Now and Building for the Future

    Slide 5: We Are Delivering Now and Building for the Future

    We Are Delivering Now and Building for the Future 5 Foundation Strategic Differentiators Demonstrated Proof Points Growth and Expansion HSC Gene Therapy Platform Approach Scientific & Medical Safety + durability over 160 patients treated Larger indications Clinical efficacy across 6 indications Manu

  6. Slide 6: HSC Gene Therapy Offers a Highly Differentiated Approach

    Slide 6: HSC Gene Therapy Offers a Highly Differentiated Approach

    HSC Gene Therapy Offers a Highly Differentiated Approach 6 Monocyte / Macrophage T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Literature references: Alessia Capotondo, Rita Milazzo, Letterio Salvatore Politi, Angelo Quattrini, Alessio Palini, Tiziana Plati, Stefania Merella, Alessa

  7. Slide 7: Durability of Response and Safety Demonstrated via Longest Patient Follow-up

    Slide 7: Durability of Response and Safety Demonstrated via Longest Patient Follow-up

    Durability of Response and Safety Demonstrated via Longest Patient Follow-up 7 Patients treated in the development phase, including in clinical trials and under pre-approval access (defined as any form of pre-approval treatment outside of a company-sponsored clinical trial, including, but not limite

  8. Slide 8: Improving the HSC Gene Therapy Manufacturing Process

    Slide 8: Improving the HSC Gene Therapy Manufacturing Process

    Improving the HSC Gene Therapy Manufacturing Process HSPC = Hematopoietic stem and progenitor cell 8

  9. Slide 9: Applying Commercial Strategy to Launch Gene Therapies Globally

    Slide 9: Applying Commercial Strategy to Launch Gene Therapies Globally

    Applying Commercial Strategy to Launch Gene Therapies Globally Leverage for Libmeldy and future launches 9 Enable Patient ID & Diagnostics Multi-pronged diagnostics initiatives and newborn screening in EU and U.S. Expand Geographic Footprint Qualifying leading centers with transplant and disease are

  10. Slide 10: HSC Gene Therapy: Meeting the Need in Severe Neurodegenerative Disorders

    Slide 10: HSC Gene Therapy: Meeting the Need in Severe Neurodegenerative Disorders

    HSC Gene Therapy: Meeting the Need in Severe Neurodegenerative Disorders 10

  11. Slide 11: Clinical Efficacy in Multiple Devastating, Rapidly Progressive Diseases

    Slide 11: Clinical Efficacy in Multiple Devastating, Rapidly Progressive Diseases

    Clinical Efficacy in Multiple Devastating, Rapidly Progressive Diseases 11 LI, late infantile; EJ, early juvenile CI, confidence interval; GMFM, gross motor function measurement; MLD, metachromatic leukodystrophy; Both LI and EJ patients (EJ not shown) achieved a statistically significant difference

  12. Slide 12: New Clinical Data from Three Neurodegenerative Programs Coming at WORLDSymposium

    Slide 12: New Clinical Data from Three Neurodegenerative Programs Coming at WORLDSymposium

    12 New Clinical Data from Three Neurodegenerative Programs Coming at WORLDSymposium™ Nine Orchard Abstracts Accepted Showcasing Strength of HSC Approach

  13. Slide 13: Growing Neurodegenerative Portfolio from Rare to Larger Indications

    Slide 13: Growing Neurodegenerative Portfolio from Rare to Larger Indications

    Growing Neurodegenerative Portfolio from Rare to Larger Indications 13 GRN-FTD Research program ALS New research program Discovery pipeline* MPS-I MPS-IIIA MPS-IIIB MPS-IIIB Preclinical MPS-I POC to pivotal 2021 MPS-IIIA Fully enroll POC 2021 MLD Larger neurodegenerative diseases *Other undisclosed

  14. Slide 14: HSC Gene Therapy Is Highly Suited for GRN-FTD

    Slide 14: HSC Gene Therapy Is Highly Suited for GRN-FTD

    Knopman DS, Roberts RO. J Mol Neurosci. 2011, Onyike CU, Diehl-Schmid J. Int Rev Psychiatry. 2013 and Riedl L, et al Neuropsychiatr Dis Treat. 2014 HSC Gene Therapy Is Highly Suited for GRN-FTD: a Large and Growing Opportunity 14

  15. Slide 15: HSC Gene Therapy: Advancing the Treatment Landscape in Immunological Disorders

    Slide 15: HSC Gene Therapy: Advancing the Treatment Landscape in Immunological Disorders

    HSC Gene Therapy: Advancing the Treatment Landscape in Immunological Disorders 15

  16. Slide 16: Compelling Evidence in Immunological Disorders

    Slide 16: Compelling Evidence in Immunological Disorders

    16 Elimination of severe bleeds OTL-103 for WAS Moderate or severe bleeds Data published January 2020 in Nature Medicine † patient deceased from advanced disease; Excludes data from 1 patient treated with drug product deemed by the investigator to be different from the OTL-102 drug product Functiona

  17. Slide 17: HSC Transplants Give Rise to Tissue Macrophages

    Slide 17: HSC Transplants Give Rise to Tissue Macrophages

    HSC Transplants Give Rise to Tissue Macrophages with the Potential to Reconstitute Functional Gut Innate Immunity 17

  18. Slide 18: Clinical Validation in X-CGD Supports Application in Larger Populations

    Slide 18: Clinical Validation in X-CGD Supports Application in Larger Populations

    Clinical Validation in X-CGD Supports Application in Larger Populations such as NOD2 Crohn’s Disease 18 Proof of concept in rare form of colitis NOD2-CD Research program X-CGD More common forms of colitis

  19. Slide 19: OTL-104 for NOD2-Crohn's Represents a Significant Commercial Opportunity

    Slide 19: OTL-104 for NOD2-Crohn's Represents a Significant Commercial Opportunity

    OTL-104 for NOD2-Crohn’s Represents a Significant Commercial Opportunity 19 1,2 CD prevalence estimates: Centers for Disease Control and Prevention; European Crohn’s and Colitis Organisation (ECCO) 3 NOD2: Ashton, James J et al.Clin Transl Gastroenterol. 2020 Feb

  20. Slide 20: Operations and Upcoming Milestones

    Slide 20: Operations and Upcoming Milestones

    Operations and Upcoming Milestones 20

  21. Slide 21: Today's Roadmap for a Sustainable Future

    Slide 21: Today's Roadmap for a Sustainable Future

    Today’s Roadmap for a Sustainable Future 21 1 YE 2020 cash of $192M Access equity markets following inflection points Supplement with non-dilutive capital 2 Focus on highest value programs Allocate R&D capital for larger indications Stage investments in additional rare disease programs 3 Invest for

  22. Slide 22: 2021 is Rich in Expected Milestones Spanning Development and Commercialization

    Slide 22: 2021 is Rich in Expected Milestones Spanning Development and Commercialization

    2021 is Rich in Expected Milestones Spanning Development and Commercialization 22 Building a fully integrated company Clinical Regulatory Commercial OTL-204: Announce data from GRN-FTD research program OTL-104: Announce data from NOD2-CD research program OTL-203: Initiate registrational study for MP

  23. Slide 23: $192M in cash as of YE 2020 and runway into first half of 2022

    Slide 23: $192M in cash as of YE 2020 and runway into first half of 2022

    $192M in cash as of YE 2020 and runway into the first half of 2022 Compelling Fundamentals Driving Near and Long-term Growth 23 1x treatment – HSC gene therapy approach offers curative potential Strong clinical track record – over 160 patients treated Clinical validation in rare diseases increases c

Source: SEC EDGAR · 8-K filed Jan 11, 2021

More decks from Orchard Therapeutics PLC